Pfizer will list its COVID-19 treatment Paxlovid at a price of $1,390 per five-day course when it soon hits the commercial market, the drugmaker confirmed to Axios.
Why it matters: Paxlovid’s new listed price, first reported by the Wall Street Journal, will be more than twice the $529 paid by the federal government, which until now has maintained the entire U.S. supply of the key antiviral medication.
Ah, that was the era of omicron. We’re over 21 months and several variants past that now, and I was given the information about paxlovid last week.
Also, that study only covers a single month in Israel in 2022 and only 2.6% of the sample was given paxlovid.
Your secret information that you decline to share…
Paxlovid obviously works, or they couldn’t raise the price of it. Insurance wouldn’t cover it.
I shared it. A medical professional told me.